<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03858075</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-782-0101</org_study_id>
    <nct_id>NCT03858075</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BLU-782 When Administered Orally to Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this study are to assess the safety, tolerability, pharmacokinetics
      (PK), and food effect of BLU-782 in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Actual">September 11, 2019</completion_date>
  <primary_completion_date type="Actual">September 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs) through Day 8 with a single dose of BLU-782.</measure>
    <time_frame>Baseline to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs) through Day 17 with multiple doses of BLU-782 .</measure>
    <time_frame>Baseline to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the concentration-time profile of BLU-782 in plasma through day 20 when taken with or without food.</measure>
    <time_frame>Baseline to Day 20</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single ascending doses with BLU-782</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ascending doses with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending doses with BLU-782</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending doses with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Food effect of BLU-782 taken with food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Food effect of BLU-782 taken without food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLU-782</intervention_name>
    <description>oral capsules</description>
    <arm_group_label>Food effect of BLU-782 taken without food</arm_group_label>
    <arm_group_label>Multiple ascending doses with BLU-782</arm_group_label>
    <arm_group_label>Single ascending doses with BLU-782</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral capsules</description>
    <arm_group_label>Multiple ascending doses with placebo</arm_group_label>
    <arm_group_label>Single ascending doses with placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLU-782 taken with food</intervention_name>
    <description>oral capsules</description>
    <arm_group_label>Food effect of BLU-782 taken with food</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically healthy

          -  Non-smoker

          -  Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2

          -  No clinically significant cardiac history

          -  No current electrocardiogram (ECG) abnormality

          -  Female must not be of childbearing potential

        Exclusion Criteria:

          -  History of or current mental or legal incapacitation or major emotional problems

          -  History or current clinically significant medical/psychiatric condition/disease

          -  History of any illness that, in the opinion of the Investigator, might impact the
             results of the study or pose an additional risk to the participant

          -  History or current alcoholism/drug abuse

          -  History or current allergy to the study drug or a similar drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Undisclosed</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

